In research products - R & D Center - Product and R & D - Wuhan Youzhiyou Biopharmaceutical -大发彩票平台

Product & Development

Developing innovative medicines to safeguard human health

Product under development

M701 (EpCAM×CD3 bispecific Antibody)

Product features and advantages

It is mainly used to relieve EpCAM positive tumor-associated malignant ascites (MA) and malignant pleural effusion (MPE).
The same target drug cartuxumab has been used in clinical treatment of malignant ascites, and its efficacy is obvious.
Phase II clinical trials of M701 in patients with malignant ascites (MA) and Phase Ib/ II clinical trials of M701 in patients with malignant pleural effusion (MPE) are currently underway。

Y101D (PD-L1×TGF - beta. bispecific antibody)

Product features and advantages

It is mainly used to treat a variety of solid tumors;
Anti-tgf-β can effectively regulate TME and enhance immune efficacy;
Combined with chemotherapy drugs can enhance the effect of chemotherapy drugs;
It is the only PD-L1× TGF - beta. symmetric quadrivalent bispecific antibody to enter clinical development in the world.
The Phase Ib/II clinical trial of combination chemotherapy for pancreatic cancer has received IND approval from the National Drug Administration (NMPA)。

Y150 (CD38×CD3 bispecific antibody)

Product features and advantages

It is mainly used to treat refractory or recurrent, refractory multiple myeloma (rrMM).
There are 22 CD38 targeted antibody candidates or fusion proteins in clinical development globally (excluding China) and 9 in China for the treatment of MM, respectively.
Y150 is the only bi-specific antibody targeting CD38 and T cell conjugation that has entered clinical development in China。

Y2019 (RBD dimeric subunit SARS-CoV-2 vaccine)

Product features and advantages

The dimer has stable structure and strong immunogenicity.
Does not contain any active virus, the risk of disease is low;
Developed in collaboration with Wuhan Institute of Virology, Chinese Academy of Sciences。

M802 (HER2×CD3 bispecific antibody)

Product features and advantages

It is mainly used to treat HER2-positive solid tumors.
The completed Phase I clinical trial data showed overall safety and good tolerability.

Y400 (VEGFxANG2 bisspecific Antibody)

Product features and advantages

Wet age-related macular degeneration (wAMD) is a major disease with a high incidence of the elderly, with 3.9 million Chinese patients in 2021, and about 20 million Chinese patients, which represents a huge market.
VEGF and ANG2 were double blocked, and the therapeutic mechanism was stronger.
The ultra high concentration preparation of 140mg/ml is used for intravitreal injection;
On July 26, 2022, Youzhi Youxin entered into an asset transfer agreement with Kangzhe Weisheng to transfer all rights and assets related to Y400 to Kangzhe Pharmaceutical。